Predicting Prognosis in Patients with Superficial Bladder Cancer

ONCOLOGY

Volumn 12, Issue 12, 1998, Pages 1717-1723

  Devere White, Ralph W ^b   Stapp, Eschelle ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0005479569     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. American Cancer Society: Cancer Facts and Figures 1998, pp 1-18. Atlanta, Georgia, American Cancer Society. 1998.
2. Ismail MT. Lattime EC, Gomela LG: Current management of superficial bladder cancer: BCG and beyond. Monogr Urol 19:33-55, 1998.
3. Clayson DA. Cooper EH: Cancer of the urinary tract. Adv Cancer Res 13:271-381, 1970.
4. Price JM: Etiology of Bladder Cancer: Benign and Malignant Tumors of the Urinary Bladder, pp 189-251. Flushing, New York, Medical Examination Publishing. 1971.
5. Ross RK, Paganini-Hill A, Henderson B: Diagnosis and Management of Genitourinary Cancer, pp 23-31. Philadelphia, Saunders, 1988.
6. Herr HW: Natural history of superficial bladder tumors: 10-20 year follow-up of treated patients. World J Urol 15:84-88, 1997.
7. Heney NM: Natural history of superficial bladder cancer Prognostic features and long-term disease course. Urol Clin North Am 19:429-433, 1992.
8. Heney NM, Ahmed S, Flanagan MJ: Superficial bladder cancer: Progression and recurrence. J Urol 130:1083-1086, 1983.
9. Fitzpatrick JM, West AB, Buller MR: Superficial bladder tumors: The importance of recurrence pattern following initial resection. J Urol 135:920-924, 1986.
10. Sobin LH, Wittekind CH (eds): TNM Classification of Malignant Neoplasms. New York, Wiley-Liss, 1997.
11. Lutzeyer W. Rubber H, Dahm H: Prognostic parameters in superficial bladder cancer: An analysis of 315 Cases. J Urol 127:250-252, 1982.
12. Torti FM, Lum BL, Aston D, et al: Superficial bladder cancer: The primacy of grade in the development of invasive disease. J Clin Oncol 5:125-130, 1987.
13. Holmang S, Hedelin H, Anderstrom C, et al: The relationship among multiple recurrences, progression ad prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 153:1823-1826, 1995.
14. Kurth K. Tunn U. Ay R, et al: Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, etho- glucid and transurethral resection alone. J Urol 158:378-384, 1997.
15. Herr HW, Wartinger DD. Fair WR, et al: Bacillus Calmette-Guerin therapy for superficial bladder cancer: A 10-year follow-up. J Urol 147:1020-1023, 1992.
16. Holmang S, Hedelin H, Anderstrom C, et al: The importance of the depth of invasion in stage T1 bladder carcinoma: A prospective cohort study. J Urol 157:800-804, 1997.
17. Hasui Y, Osada Y, Kitada S, et al: Significance of invasion to the muscularis mucosa on the progression of superficial bladder cancer. Urology 43:782-786, 1994.
18. deVere White RW, Deitch AD, Tesluk H, et al: Prognostic significance of DNA ploidy in Ta/T1 bladder cancer A Southwest Oncology Group study. Urol Oncol 2:27-34, 1996.
19. deVere White RW, Deitch AD, Daneshamand S, et al: The prognostic signficance of S- phase analysis in stage Ta/T1 bladder cancer: A Southwest Oncology Group study (abstract 552). Presented at the 1998 American Urological Association meeting.
20. Tribukait B: Tumor biology in diagnostic cytology: DNA cytometry in carcinomas of the bladder and prostate. Recent Results Cancer Res 133:23-31, 1993.
21. Sauter G, Gasser TC, Moch H, et al: DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH. Urol Res 25(suppl 1):S37-S43, 1997.
22. Kamentsky LA, Kamentsky LD: Microscope-based multiparameter laser scanning cytometer yielding data comparable to flow cytometry data. Cytometry 12:381-387, 1991.
23. Stavropoulos NE, loackim-Velogianni E, Hastazeris K, et al: Growth fractions in bladder cancer defined by Ki-67: Association with cancer grade, category and recurrence rate of superficial lesions. Br J Urol 72:736-739, 1993.
24. Asakura T, Takano Y, Iki M, et al: Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer. J Urol 158:385-388, 1997.
25. Chen G, Lin MS, Li RC: Expression and prognostic value of proliferating cell nuclear antigen in transitional cell carcinoma of the urinary bladder. Urol Res 25:25-30, 1997.
26. Fukazawa S. Hashimura T, Sasaki M, et al: Nuclear morphometry for improved prediction of the prognosis of human bladder carcinoma. Cancer 76:1790-1796,1995.
27. Dalbagni G, Cordon-Cardo C: Mutations of the cell-cycle regulators in bladder carcinoma. Mol Urol 1:39-44, 1997.
28. Kastan M. Onkyekwere O, Sidransky D, et al: Participation of p53 protein in response to DNA damage. Cancer Res 51:6304-6311, 1991.
29. Velculescu VE, El-Demy WS: Biologic and clinical importance of the p53 tumor suppressor gene. Clin Chem 42:858-868,1996.
30. Hollstein M. Sidransky D. Vogelstein B. et al: p53 Mutations in human cancers. Science 253:49-53,1991.
31. Esrig D, Spruk III CH, Nichols PW, et al: p53 Nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143:1389-1397,1993.
32. Cordon-Cardo C, Dalbagni G, Saez GT, et al: p53 Mutations in human bladder cancer: Genotypic vs phenotypic patterns. Int J Cancer 56:347-353, 1994.
33. Sarkis AS, Dalbagni G. Cordon-Cardo C. et al: Nuclear overexpression of p53 protein in transitional cell bladder carcinomas: A marker of disease progression. J Natl Cancer Inst 85:53-59, 1993.
34. Thomas DJ, Robinson MC, Charlton R, et al: p53 Expression ploidy and progression in pT1 transitional cell carcinoma of the bladder, Br J Urol 73:533-537, 1993.
35. Lacombe L Dalbagni G, Zhang Z-F, et al: Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancel before and after bacillus Calmette-Guerin therapy: Correlation to clinical outcome. J Clin Oncol 14:2646-2652, 1996.
36. Vet JAM, Witues A, Marras SAE, et al: Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer. Clin Cancer Res 2:1055-1061, 1996.
37. Liukkonen TJO, Lipponen PD, Helle M, et al: Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade, and cell proliferation in superficial bladder cancer. Urol Res 25:1-8, 1997.
38. Serth J. Kuczk MA, Bokemeyer C, et al: p53 Immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 71:201- 205, 1995.
39. Malkowicz SB: Superficial bladder cancer: The role of molecular markers in the treatment of high-risk superficial disease. Semin Urol Oncol 15:l69-l78, l997.
40. Goodrich DW, Wang NP, Quiun Y-W, et al: The retinoblastoma gene product regulates progression throughout the GI phase of the cell cycle. Cell 67:293-302, 1991
41. Mittnacht S, Weinberg RA: GI/S phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment. Cell 65:381-393, 1991.
42. Riley DJ. Lee YH, Lee WH: The retinoblastoma protein: More than a tumor suppressor. Anna Rev Cell Biol 10:1 -29, 1994.
43. Presti JC Jr, Reuter VE, Galan T, et al: Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 51:5404-5409, 1991.
44. Xu H-J, Cairns P, Hu S-X, et al: Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 53:781- 784, 1993.
45. Cordon-Cardo C, Wartinger D, Petrylak D, et al: Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst 84:1251-1256, 1992.
46. Cordon-Cardo C. Zhang ZF, Dalbagni G, et al: Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 57:1217-1221, 1997.
47. Lipponeu PK, Eskelinen MJ: Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol 121:303-308, 1995.
48. Kirsh EJ, Baunoch DA, Stadler WM: Expression of bcl-2 and bcl-x in bladder cancer. J Urol 159:1348-1353, 1998.
49. Bochner BH, Cote RJ, Weidner N, et al: Angiogenesis in bladder cancer: Relationship between microvessel density and tumor progression. J Natl Cancer Inst 87:1603-1612, 1995.